As a distinct subset of HER-2 positive breast cancer, there is no data of the survival and prognosis in triple positive male breast cancer (TP-MBC) as well as outcome compared with triple positive female breast cancer (TP-FBC). This evidence concerns the gene ERBB2 and breast carcinoma.